Flare or warning sign?

What can I safely watch at home?

You can often watch familiar soreness after a clear cause. Cut back on the work that started it. Keep moving gently when that feels comfortable. Cold may help new swelling, while heat may ease stiffness. The joint should get closer to normal as you rest it. Arrange a visit when each flare lasts longer or limits more of your day.

Even familiar soreness needs care when it keeps growing.

When is a regular visit enough?

Set up a visit when soreness disturbs sleep or limits common chores. Say how long morning stiffness lasts and whether several joints swell. Bring your medicine list and questions about cost or recovery. QC Kinetix offers visits for soreness and may discuss regenerative treatments after an exam. For this non-surgical care, a clinician prepares material from your body and places it into the joint with a needle. The care isn't right for every joint or every person. A zero-to-ten pain score helps, but the exam must also cover swelling, movement, sleep and daily limits.

Tell the clinician what soreness stops you from doing.

Which signs need prompt help?

Seek help soon when a joint is hot and very swollen, especially with fever. Don't wait with sudden weakness, new numbness, a visible injury or trouble bearing weight. Loss of bowel or bladder control with spinal pain also needs quick care. After a joint procedure, quickly rising heat, swelling or illness needs a call.

Don't test these warning signs with exercise.

Sources

1. The 2019 ACR/Arthritis Foundation guideline makes STRONG recommendations for exercise, weight loss in people with overweight or obesity, self-efficacy and self-management programmes, tai chi, cane use, hand orthoses for first-CMC joint OA, tibiofemoral bracing, topical NSAIDs for the knee, oral NSAIDs and intra-articular glucocorticoid injections for the knee; acupuncture, thermal modalities, radiofrequency ablation, acetaminophen, duloxetine and tramadol are only conditional.

   Kolasinski SL, et al. — 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee.. Arthritis Rheumatol, 2020. DOI: 10.1002/art.41142.

2. OARSI designates arthritis education plus structured land-based exercise (with dietary weight management for the knee) as CORE treatments for knee, hip and polyarticular OA. Topical NSAIDs are Level 1A for knee OA. Intra-articular corticosteroids, intra-articular hyaluronic acid and aquatic exercise are Level 1B/2 for the KNEE only and are NOT recommended for hip or polyarticular OA. Acetaminophen is conditionally not recommended, and no oral NSAID is recommended for people with cardiovascular comorbidity or frailty.

   Bannuru RR, et al. — OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis.. Osteoarthritis Cartilage, 2019. DOI: 10.1016/j.joca.2019.06.011.

3. In a two-year double-blind randomized trial of 140 patients with symptomatic knee OA and ultrasonic synovitis, intra-articular triamcinolone 40 mg every 12 weeks produced significantly greater cartilage volume loss than saline (index compartment cartilage thickness change -0.21 mm vs -0.10 mm; between-group difference -0.11 mm, 95% CI -0.20 to -0.03) with NO significant difference in pain.

   McAlindon TE, et al. — Effect of Intra-articular Triamcinolone vs Saline on Knee Cartilage Volume and Pain in Patients With Knee Osteoarthritis: A Randomized Clinical Trial.. JAMA, 2017. DOI: 10.1001/jama.2017.5283.

4. A two-year randomized placebo-controlled trial in 146 participants with symptomatic knee OA raised serum 25-hydroxyvitamin D by a mean 16.1 ng/mL with cholecalciferol 2000 IU/day, testing whether vitamin D supplementation reduces symptom and structural progression of knee osteoarthritis.

   McAlindon T, et al. — Effect of vitamin D supplementation on progression of knee pain and cartilage volume loss in patients with symptomatic osteoarthritis: a randomized controlled trial.. JAMA, 2013. DOI: 10.1001/jama.2012.164487.

5. A meta-analysis of six randomized trials (860 patients, 334 receiving bone marrow aspirate concentrate) found overall complication rates of 41.91% for BMAC versus 41.25% for comparison injectables (P=0.85), with knee effusion the most common BMAC complication at 18.26% and a number-needed-to-harm of 152.

   Fucaloro S, et al. — Complication rates of bone marrow aspirate concentrate injections versus other injectable therapies for knee osteoarthritis: A systematic review and meta-analysis.. J Orthop, 2025. DOI: 10.1016/j.jor.2024.10.005.